TTrialPathMatch Me to Trials
← Back to trials
RecruitingObesityOverweightDiabetes Mellitus, Type 2

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.

Sponsor: Eli Lilly and Company

You may qualify if…

  • ✓ Have type 2 diabetes
  • ✓ Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
  • ✓ Have a BMI of ≥27 kg/m2 at screening
  • ✓ Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight

You may not qualify if…

  • ✕ Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
  • ✕ Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • ✕ Have type 1 diabetes
  • ✕ Have taken any of the following within 90 days prior to screening
  • ✕ medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
  • ✕ dipeptidyl peptidase 4 (DPP-4) inhibitors, and
  • ✕ insulin
  • ✕ Have had within 90 days prior to screening:

Where it's recruiting

Arizona

Tucson

California

Escondido · Los Alamitos · Los Angeles

Colorado

Aurora

Connecticut

Waterbury

Florida

Pembroke Pines · Weston

Georgia

Dalton

Hawaii

Honolulu

Indiana

Evansville · Indianapolis

Louisiana

Eunice · Marrero

Missouri

Springfield · St Louis

New Jersey

Warren Township

New York

New York

Source: ClinicalTrials.gov · NCT07881458 · last updated 2026-11-18